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For CAR-T and autologous ex vivo gene therapies, cells are first collected from patients via apheresis, modified 
ex vivo with lentiviral vector (LVV) or other gene addition/gene editing methods, expanded in culture, and frozen 
as a living drug product.  With the rapid growth of the cell and gene therapy field, the demand for LVV has 
increased exponentially. Current LVV production methods using transient transfection are robust but will 
ultimately be constrained volumetrically and temporally. To overcome these constraints, an alternative 
production process using stable clonal cell lines may be required to meet future demand. Stable producer cell 
lines will enable multi-day, continuous and scalable lentiviral vector production. The drug product manufacturing 
processes for autologous therapies present an ideal opportunity for continuous manufacturing, going beyond 
decentralized manufacturing to point-of-care or even bedside manufacturing. This presentation will provide an 
overview of our efforts to advance continuous bioprocessing for LVV and the challenges and opportunities of 
beside manufacturing for autologous gene therapy products. 
 
